Biotech · Private company
Kadmon, a Sanofi Company
Track this companyFree. Adds Kadmon, a Sanofi Company to your Dealase workspace and tells you when its record changes.
Clinical trials130 recruiting or active
Pipeline programs16From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline16
- BelumosudilPhase 2 · Diffuse Cutaneous Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Belumosudil (KD025)Phase 2 · Graft vs Host DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Belumosudil (KD025)Phase 2 · System; SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Belumosudil (KD025)Phase 2 · Chronic Graft-versus-host-diseaseClinicalTrials.gov · fetched Nov 12, 2026
- Belumosudil 200 mg BIDPhase 2 · Chronic Graft-versus-host-diseaseClinicalTrials.gov · fetched Nov 12, 2026
- Belumosudil 200 mg QDPhase 2 · Chronic Graft-versus-host-diseaseClinicalTrials.gov · fetched Nov 12, 2026
- Belumosudil 400 mg QDPhase 2 · Chronic Graft-versus-host-diseaseClinicalTrials.gov · fetched Nov 12, 2026
- TesevatinibPhase 2 · Polycystic Kidney, Autosomal DominantClinicalTrials.gov · fetched Nov 12, 2026
- TesevatinibPhase 2 · Autosomal Dominant Polycystic KidneyClinicalTrials.gov · fetched Nov 12, 2026
- BelumosudilPhase 1 · Immune System DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Belumosudil mesylatePhase 1 · Immune System Disorder (Healthy Volunteer)ClinicalTrials.gov · fetched Nov 12, 2026
- KD025Phase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- KD033 (SAR445710)Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- OATP1B1/BCRP victim drugPhase 1 · Immune System DisorderClinicalTrials.gov · fetched Nov 12, 2026
- P-gp victim drugPhase 1 · Immune System DisorderClinicalTrials.gov · fetched Nov 12, 2026
- UGT1A1 victim drugPhase 1 · Immune System DisorderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid TumorsPHASE1 · TERMINATED · started Mar 6, 2023ClinicalTrials.gov NCT04242147 · fetched Nov 12, 2026
- A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male SubjectsPHASE1 · COMPLETED · started Jul 27, 2022ClinicalTrials.gov NCT05806567 · fetched Nov 12, 2026
- Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213PHASE2 · COMPLETED · started Feb 23, 2022ClinicalTrials.gov NCT05305989 · fetched Nov 12, 2026
- Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic SclerosisPHASE2 · TERMINATED · started Mar 3, 2021ClinicalTrials.gov NCT04680975 · fetched Nov 12, 2026
- KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic ImpairmentPHASE1 · COMPLETED · started Dec 11, 2019ClinicalTrials.gov NCT04166942 · fetched Nov 12, 2026
- KD025 in Subjects With Diffuse Cutaneous Systemic SclerosisPHASE2 · TERMINATED · started Jun 26, 2019ClinicalTrials.gov NCT03919799 · fetched Nov 12, 2026
- Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyPHASE2 · TERMINATED · started Oct 11, 2018ClinicalTrials.gov NCT03640481 · fetched Nov 12, 2026
- Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKDPHASE2 · COMPLETED · started Oct 12, 2017ClinicalTrials.gov NCT03203642 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host DiseasePHASE2 · COMPLETED · started Sep 15, 2016ClinicalTrials.gov NCT02841995 · fetched Nov 12, 2026
- A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female SubjectsPHASE1 · COMPLETED · started Mar 28, 2014ClinicalTrials.gov NCT05918614 · fetched Nov 12, 2026
- A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female SubjectsPHASE1 · COMPLETED · started Nov 21, 2013ClinicalTrials.gov NCT05918588 · fetched Nov 12, 2026
- A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney DiseasePHASE1_PHASE2 · COMPLETED · started Oct 11, 2012ClinicalTrials.gov NCT01559363 · fetched Nov 12, 2026
- A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male SubjectsPHASE1 · COMPLETED · started Sep 21, 2009ClinicalTrials.gov NCT05918627 · fetched Nov 12, 2026